NASH patients had higher Fibroscan scores, 12.9 (10.6; 14.5 kPA), than NAFL patients 6.3 (5.2; 7.8) (P ≤ 0.0001); and similarly had elevated liver enzymes when compared with NAFL patients; ALT (57 vs 38 IU/L; P = 0.0394), AST (52 vs 26 IU/L; P ≤ 0.0001), and GGT (97 vs 53 IU/L; P = 0.0178). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.